Subject(s)
Lithiasis/diagnosis , Testicular Diseases/diagnosis , Ureaplasma Infections/diagnosis , Ureaplasma urealyticum , Urethral Diseases/microbiology , Urinary Tract Infections/diagnosis , Adult , Anti-Bacterial Agents/therapeutic use , Diagnosis, Differential , Doxycycline/therapeutic use , Humans , Lithiasis/complications , Lithiasis/pathology , Male , Testicular Diseases/complications , Testicular Diseases/pathology , Ureaplasma Infections/complications , Ureaplasma Infections/drug therapy , Urethral Diseases/complications , Urethral Diseases/drug therapy , Urinary Tract Infections/complications , Urinary Tract Infections/drug therapyABSTRACT
Bromocriptine, used in the treatment of acromegaly, hyperprolactinemia and Parkinson's disease, may be responsible in this last case, for pleuro-pulmonary complications in higher doses. Since 1981 about thirty cases were described. It was mostly pleural effusions, pleural thickening and parenchymal lung fibrosis. The prevalence of pleuro-pulmonary diseases is between 2 to 5% after 5 years with bromocriptine that varied in dosage from 20 to 90 mg daily. The patients developed symptoms from nine months to four years. We report a case of a patient treated for one year for Parkinson's disease with daily dose of 105 mg of bromocriptine in whom bilateral pulmonary infiltrate was discovered with a deterioration in the general physical state and dyspnea. There was a favorable clinical and chest roentgenogram outcome following the cessation of treatment, in six months. The hypotheses to explain the pathogenesis of these disorders were always discussed: a vascular theory, an immunological theory or a toxic fibrogenesis induced by the molecule acting on dopaminergic receptors and serotonergic synapses. Now, in our knowledge, these complications justify a clinical and chest roentgenogram follow up for any patients treated with bromocriptine.